Merja A. Neukamm

2 papers in the library · 51 citations · publishing 2020-2021

Papers

Use of the CytoSorb adsorption device in MDMA intoxication: a first-in-man application and in vitro study

Intensive Care Medicine Experimental June 21, 2020 Corinna N. Lang, Michaela J. Sommer, Merja A. Neukamm et al. 31 citations

A 21-year-old man with severe MDMA (ecstasy) overdose and multi-organ failure—including neurological impairment, hyperpyrexia, rhabdomyolysis, kidney and liver failure, and bleeding—was treated with a CytoSorb adsorber device. His serum MDMA concentration fell from 540 to 140 ng/ml within the first 24 hours, and levels of interleukin 6 and myoglobin also decreased, followed by clinical improvement and full recovery. In vitro, the device removed MDMA to undetectable levels. The authors suggest early use of the adsorber may help manage severe MDMA intoxication, though they cannot prove the clinical improvement was directly due to MDMA removal or to effects on rhabdomyolysis, hyperinflammation, or liver failure.

DOI: 10.1186/s40635-020-00313-3 Full text MDMA Intoxication Multi-organ failure Adsorption

Psychotomimetic symptoms after a moderate dose of a synthetic cannabinoid (JWH-018): implications for psychosis

Psychopharmacology January 26, 2021 Eef L. Theunissen, Johannes T. Reckweg, Nadia R. P. W. Hutten et al. 20 citations

A moderate dose of the synthetic cannabinoid JWH-018, inhaled by 24 healthy adults with no history of mental illness, produced pronounced psychedelic and dissociative effects, including altered perception, amnesia, derealization, depersonalization, and confusion. The average dose administered was 5.52 mg. These findings indicate that synthetic cannabinoids pose a serious risk for public health by inducing psychotomimetic symptoms even in people without prior mental health issues.

DOI: 10.1007/s00213-021-05768-0 Full text Cannabis Psychotomimetic Psychosis Synthetic cannabinoids +8